

**Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.**

---

## Hyperbaric and Topical Oxygen Therapy

**MP9055**

**Covered Service:** Yes

### **Prior Authorization**

**Required:** No

**Additional Information:** Self-funded plans (ASO) may require prior authorization. Please refer to the member's Summary Plan Document (SPD) or call the Customer Service number found on the member's card for specific prior authorization requirements.

### **Prevea360 Health Plan Medical Policy:**

1.0 Hyperbaric Oxygen therapy (HBO) therapy **does not require** prior authorization and is considered medically necessary for **ANY** of the following indications approved by the Hyperbaric Oxygen Therapy Committee of the Undersea and Hyperbaric Medicine Society has approved the following uses of HBOT:

- 1.1 Refractory osteomyelitis
- 1.2 Idiopathic sudden sensorineural hearing loss (when used within 2 weeks of symptoms onset)
- 1.3 Compromised grafts and flaps
- 1.4 Radiation injury (delayed) – soft tissue and bony necrosis
- 1.5 Carbon monoxide poisoning, including carbon monoxide poisoning complicated by cyanide poisoning
- 1.6 Acute thermal burn injury
- 1.7 Arterial insufficiencies such as central retinal artery occlusion, and enhancement of healing in select problem wounds
- 1.8 Crush injury, compartment syndrome, and other acute traumatic ischemias
- 1.9 Clostridial myositis and myonecrosis (gas gangrene)
- 1.10 Decompression sickness
- 1.11 Necrotizing soft tissue infections
- 1.12 Air or gas embolism
- 1.13 Severe anemia
- 1.14 Intracranial abscess

**Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.**

- 2.0 Hyperbaric oxygen therapy is considered experimental and investigational, and therefore not medically necessary for all other indications, including but not limited to **ANY** of the following:
- 2.1 Traumatic or chronic brain injury
  - 2.2 Cerebral palsy
  - 2.3 Multiple sclerosis
  - 2.4 Stroke
  - 2.5 Autism
- 3.0 Topical oxygen therapy, including hyperbaric topical oxygen therapy (HTOT) and continuous topical oxygen therapy (CTOT), are considered experimental and investigational, and therefore not medically necessary.

<b>Document</b>	<b>Committee/Source</b>	<b>Date(s)</b>
<b>Created:</b>	QA/UR Committee	August 20, 1991
<b>Revised:</b>	Utilization Management Committee/Concurrent Review Dept.	September 10, 1997
	Utilization Management Committee/ HAYES, Inc.	September 8, 1999
	Utilization Management Committee/ Medicare Part B, 7/2000	February 14, 2001
	Utilization Management Committee/ Medical Director/ Medicare Part B 5/2003	September 10, 2003
	Utilization Management Committee/Medical Affairs	April 12, 2006
	Utilization Management Committee/Medical Affairs	July 9, 2008
	Medical Director Committee/Medical Affairs	June 16, 2010
	Medical Director Committee/Medical Affairs	April 17, 2013
	Medical Policy Committee/Quality and Care Management Division	April 20, 2016
	Medical Policy Committee/Quality and Care Management Division	April 19, 2017
	Medical Policy Committee/Quality and Care Management Division	February 21, 2018
	Medical Policy Committee/Health Services Division	February 20, 2019
	Medical Policy Committee/Health Services Division	February 19, 2020
	Medical Policy Committee/Health Services Division	February 17, 2021
	Medical Policy Committee/Health Services Division	February 16, 2022
	Medical Policy Committee/Health Services Division	January 18, 2023
	Medical Policy Committee/Health Services Division	December 20, 2023
<b>Reviewed:</b>	Health Services	February 23, 1999

**Coverage of any medical intervention discussed in a Prevea360 Health Plan medical policy is subject to the limitations and exclusions outlined in the member's benefit certificate or policy and to applicable state and/or federal laws.**

<b>Reviewed:</b>	<b>Committee/Source</b>	<b>Date(s)</b>
	Managed Care Division/ Medical Affairs Department	March 20, 2000
	Managed Care Division / Medical Affairs Department	April 11, 2001
	Utilization Management Committee/CMO/Director UM	March 13, 2002
	UM Committee (UMC)/Director UM/UMC Chair	March 10, 2004
	UM Committee (UMC)/Director UM/UMC Chair Reformatted	March 9, 2005
	UM Committee (UMC)/Director UM/ UMC Chair	October 2005
	UM Committee (UMC)/Director UM/ UMC Chair	March 8, 2006
	UM Committee (UMC)/Director UM/ UMC Chair	March 14, 2007
	UM Committee (UMC)/Director UM/ UMC Chair	March 12, 2008
	UM Committee (UMC)/Director UM/UMC Chair	April 8, 2009
	Medical Director Committee/Medical Affairs	June 16, 2010
	Medical Director Committee/Medical Affairs	June 23, 2011
	Medical Director Committee/Medical Affairs	June 20, 2012
	Medical Director Committee/Medical Affairs	August 15, 2012
	Medical Director Committee/Medical Affairs	April 17, 2013
	Medical Director Committee/Medical Affairs	April 16, 2014
	Medical Director Committee/Medical Affairs	April 15, 2015
	Medical Policy Committee/Quality and Care Management Division	April 20, 2016
	Medical Policy Committee/Quality and Care Management Division	April 19, 2017
	Medical Policy Committee/Quality and Care Management Division	February 21, 2018
	Medical Policy Committee/Health Services Division	February 20, 2019
	Medical Policy Committee/Health Services Division	February 19, 2020
	Medical Policy Committee/Health Services Division	February 17, 2021
	Medical Policy Committee/Health Services Division	February 16, 2022
	Medical Policy Committee/Health Services Division	January 18, 2023
	Medical Policy Committee/Health Services Division	December 20, 2023

Published: 01/01/2024

Effective: 01/01/2024